Targeted therapeutic options and future perspectives for HER2-positive breast cancer

Jiani Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Signal Transduction and Targeted Therapy
September 12, 2019
10.1038/s41392-019-0069-2
Cited by 406

Related Papers

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
|npj Breast Cancer|2020|74
Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial
|Frontiers in Pharmacology|2021|51
Molecular landscape of <scp><i>TP53</i></scp> mutations in breast cancer and their utility for predicting the response to <scp>HER</scp>‐targeted therapy in <scp>HER2</scp> amplification‐positive and <scp>HER2</scp> mutation‐positive amplification‐negative patients
|Cancer Medicine|2022|27